Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Polycythaemia vera (PV), drawn from the whole corpus: 19 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No treatment has yet been shown to prevent progression to myelofibrosis or leukaemia; interferon's molecular responses are the strongest hint.
Risk stratification still rests on age and clot history; leukocyte count, allele burden and additional mutations are not yet built into treatment decisions.
Whether low-risk patients should have early cytoreduction (Low-PV suggests yes for interferon) remains unsettled and depends on cost and tolerability.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · HTA decisions.
Aquagenic pruritus and fatigue are under-treated and poorly measured in trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Hepcidin mimetics control counts but their effect on thrombosis and long-term outcomes is not yet known.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 24 changes by month →When this page itself was last checked or edited.
Erythrocytosis in adults with polycythaemia vera
FDA approval for phlebotomy-dependent polycythaemia vera.
Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.
Rusfertide added to standard care made most patients phlebotomy-free over weeks 20 to 32.
Complete response within 1 year: 43% vs 26%; complete response associated with better event-free survival.